# ADC Therapeutics (ADCT) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/ADCT
## Company Profile
- Ticker: ADCT
- Exchange: NYSE
- Sector: Biopharma
- Location: Switzerland
- Tags: ADCs, Oncology
## Stock Data
- Close: 1.27 USD
- Market cap: 403195970.86 USD
- Last updated: 2026-10-06
## Business Overview
### Antibody-Drug Conjugate Company
ADC Therapeutics is a commercial-stage oncology company focused on antibody-drug conjugates. Its capabilities span clinical development, manufacturing, medical affairs, and commercialization, with a current strategic focus on the CD19-directed medicine ZYNLONTA.
### ZYNLONTA Commercial Franchise
ZYNLONTA, or loncastuximab tesirine, is approved in the United States and conditionally approved in Europe for relapsed or refractory diffuse large B-cell lymphoma after at least two prior lines of systemic therapy. The company markets the product in later-line disease while working toward broader use and full approval.
### Earlier-Line DLBCL Development
LOTIS-5 evaluated ZYNLONTA with rituximab, while LOTIS-7 evaluates ZYNLONTA with glofitamab in relapsed or refractory DLBCL. The company is assessing the regulatory and Phase 3 paths for these combinations following FDA feedback and completion of LOTIS-7 enrollment.
### Expansion Across B-Cell Malignancies
Investigator-sponsored studies are evaluating ZYNLONTA in follicular lymphoma and marginal zone lymphoma. These programs may support publication, treatment-guideline inclusion, breakthrough designation requests, and development in disease settings beyond DLBCL.
### Focused Commercial and Regulatory Organization
ADC Therapeutics has reorganized around ZYNLONTA's commercial opportunity and the regulatory work needed to sustain and expand the franchise. This narrower structure prioritizes clinical evidence, manufacturing, medical affairs, and market access for a single core asset.
## Why The Stock Is Moving

As of Oct 6, 2026, ADCT closed up 3.25% at $1.27. No new same-company headline was identified in the current news window.

## Future Catalysts

- Presentation of LOTIS-5, LOTIS-7, and marginal zone lymphoma data at the 2026 ASH Annual Meeting.
- Update on the regulatory strategy and timing for obtaining full approval of ZYNLONTA following the LOTIS-5 pre-sBLA meeting.
- Submission of LOTIS-7 and marginal zone lymphoma data for FDA Breakthrough Therapy designation in 2026.
- Presentation of updated follicular lymphoma data in the second quarter of 2027.

## Recent News
- 2024-10-02 11:33 EST — [ADC Therapeutics gewährt neuen Mitarbeitern Zuteilungen im Rahmen des Anreizplans](https://biopharmsignal.com/news/ADCT/adc-therapeutics-gew-hrt-neuen-mitarbeitern-zuteilungen-im-rahmen-des-anreizplan-4186db9a) — Source: ADC Therapeutics
- 2024-10-01 20:05 EST — [ADC Therapeutics Makes Grants to New Employees Under Inducement Plan](https://biopharmsignal.com/news/ADCT/adc-therapeutics-makes-grants-to-new-employees-under-inducement-plan-950a18b9) — Source: ADC Therapeutics
- 2024-09-03 11:15 EST — [ADC Therapeutics hält Vorträge auf bevorstehenden Investorenkonferenzen](https://biopharmsignal.com/news/ADCT/adc-therapeutics-h-lt-vortr-ge-auf-bevorstehenden-investorenkonferenzen-d3528e20) — Source: ADC Therapeutics
- 2024-09-03 11:15 EST — [ADC Therapeutics to Present at Upcoming Investor Conferences](https://biopharmsignal.com/news/ADCT/adc-therapeutics-to-present-at-upcoming-investor-conferences-f7d93f52) — Source: ADC Therapeutics
- 2024-08-06 22:51 EST — [ADC Therapeutics berichtet über Finanzergebnisse des zweiten Quartals 2024 und gibt aktuelle Informationen zum Geschäftsbetrieb bekannt](https://biopharmsignal.com/news/ADCT/adc-therapeutics-berichtet-ber-finanzergebnisse-des-zweiten-quartals-2024-und-gi-360067de) — Source: ADC Therapeutics